Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06536465 · ClinicalTrials.gov registry record · Phase 2
The Clostridioides Difficile Trial of REC-3964
A Phase 2 study, sponsored by Recursion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT06536465 is a Phase 2 study that was terminated before completion, run by Recursion Pharmaceuticals. The registered enrollment target is 3 participants.
The verdict
NCT06536465, a Phase 2 study, was terminated before completion, sponsored by Recursion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC-3964 (doses of either 250 mg or 500 mg PO every 12 hours) for the reduction of Clostridioides difficile infection (CDI).
Interventions
- DRUG REC-3964
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2025-05-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06536465
The ClinicalTrials.gov registry entry for NCT06536465 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Recursion Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which REC-3964 is the first listed.
NCT06536465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06536465 about?
NCT06536465 is a clinical study titled "The Clostridioides Difficile Trial of REC-3964". This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC-3964 (doses of either 250 mg or 500 mg PO every 12 hours) for the reduction of Clostridioides difficile infection (CDI).
What is the current status of trial NCT06536465?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2024-10-14. Estimated completion is 2025-05-06.
What interventions are being tested in trial NCT06536465?
The interventions under investigation include: REC-3964 (DRUG).
Who is sponsoring clinical trial NCT06536465?
This trial is sponsored by Recursion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.